<DOC>
	<DOCNO>NCT00461019</DOCNO>
	<brief_summary>Congestive Heart Failure result number disease affect heart , cause heart 's failure properly meet body demand blood circulation . In spite advance drug therapy , remain significant public health problem . Pharmacologic antagonism beta-adrenergic receptor shift autonomic balance direction great vagal influence well-proven treatment heart failure patient , although patient tolerate , partially benefit treatment . It prove past well establish parasympathetic nerve stimulation slow rate heart reduce workload heart . Therefore , potential benefit vagus nerve stimulation , hence parasympathetic activation , treatment heart failure substantial . In study , safety efficacy new vagus nerve stimulate system evaluate . This study compare whether new device improve Heart Failure parameter Class II - III Heart Failure patient .</brief_summary>
	<brief_title>CardioFit™ Treatment Heart Failure</brief_title>
	<detailed_description>- Purpose study : To determine safety efficacy CardioFit™ system treatment Class II-III Heart Failure patient . - Study hypothesis : CardioFit system treatment improve patient Heart Failure parameter . - Tested hypothesis : Thirty patient require provide 80 % power 95 % confidence level order detect 12 point difference quality life questionnaire pre- post activation . - Design : Prospective , self-controlled interventional study compose 5 period : Pre-implantation , Implantation , Device activation , Follow-up ( active device ) post-study extension period . - Study duration 7.5-months per patient . At end study , patient enter extension period ( active device ) monitor quality life survival , 3 year post-implantation 6-months interval . - Study Endpoints : - Primary endpoint : The occurrence system and/or procedure related adverse event . - Secondary endpoint : change follow individual variable well composite score individual variable change : NYHA class ; Quality Life ; Exercise capacity ( 6-min walk ) ; LV Ejection fraction ; LV end-systolic end-diastolic volume ; blood test . - Up 10 participate center Europe , Israel Australia</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . The patient chronic heart failure , NYHA IIIII . The patient may previously class IV must class II III three month prior study entry ; 2 . Age 18 75 year ; 3 . The patient male postmenopausal female . Females childbearing age may include pregnancy exclude acceptable contraception measure use ; 4 . Patient must sign approve informed consent form . Patient agree attend followup evaluation ; 5 . Patient sinus rhythm . Average 24hour heart rate 60 110 b/min record 24h Holter measurement ; 6 . Patient optimal medical treatment change treatment previous 3 month exception diuretic ; 7 . Left ventricular ejection fraction estimate echocardiography , cardiac angiography , radionuclide study , accept mode evaluation , 35 % ; 8 . Patient physically capable willing perform repeat physically demand test associate study . 1 . Presence immediately life threaten condition disease heart failure , cancer , terminal renal failure etc . 2 . Acute myocardial Infarction ( MI ) , variant angina pectoris , unstable angina acute coronary syndrome previous three month ; 3 . Previous stroke ; 4 . Coronary Artery Bypass Surgery ( CABG ) Percutaneous Coronary Intervention past 3 month ; 5 . Episode NYHA class IV heart failure , include acute pulmonary oedema previous three month ; 6 . Heart failure due acute myocarditis . Restrictive constrictive pericarditis , haemodynamically significant aortic valve insufficiency aortic stenosis , mitral valve stenosis ; 7 . Severe renal hepatic failure ( Creatinine level &gt; 3 mg % ( 265 micromole/liter ) transaminase level four time ULN ) ; 8 . Diabetes Mellitus treat insulin two year prior study entry ; 9 . Diabetic neuropathy ; 10 . Previous neck surgery , include Peripheral Vascular Disease ( PVD ) , malignancy , previous irradiation therapy neck ; 11 . Current hypotension ( systolic blood pressure 80 mmHg ) ; 12 . Active peptic disease history upper GI bleeding ; 13 . Asthma , severe COPD ( e.g . FEV1 &lt; 1.5 liter ) , severe restrictive lung disease ; 14 . 1st degree AV block PR interval &gt; 240msec , 2nd 3rd degree AV block ; 15 . Atrial fibrillation flutter previous 3 month ; 16 . Sustained ventricular tachyarrhythmia hemodynamic compromise , absence implant ICD ; 17 . Long QT syndrome , congenital acquire ; 18 . Recorded suspected symptomatic vasovagal response ; 19 . Treatment investigational drug device within past 3 month ; 20 . Glaucoma , history glaucoma ; 21 . Major psychiatric disorder present past ; Dementia ; 22 . Patients transplant tissue organ ; 23 . Immunosuppressed patient ; patient systemic steroid treatment ; 24 . Anemia Hb &lt; 10gr/L , unless treat Epo ; 25 . Patients risk carotid artery plaque unstable carotid plaque , assess Echo Doppler ; and/or patient &gt; 70 % carotid artery stenosis ; 26 . Patient candidate cardiac resynchronization device implantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>